Endocrine Pharmacology
Hypothyroidism is a clinical syndrome resulting from insufficient thyroid hormone production, characterized by decreased metabolic rate and reduced sympathetic nervous system activity. Primary hypothyroidism (95% of cases) results from thyroid gland dysfunction, most commonly autoimmune thyroiditis (Hashimoto's disease), while secondary and tertiary forms arise from pituitary or hypothalamic failure, respectively. Pharmacologic management centers on thyroid hormone replacement therapy, with levothyroxine (synthetic T4) as the standard of care due to its consistent bioavailability, long half-life, and physiologic conversion to active T3.
📋 Abbreviations Used in This Article
- TSH: Thyroid-Stimulating Hormone
- T3: Triiodothyronine
- T4: Thyroxine (Levothyroxine)
- TRH: Thyrotropin-Releasing Hormone
- TPO: Thyroid Peroxidase
- TBG: Thyroxine-Binding Globulin
- IV: Intravenous
- GI: Gastrointestinal
- PPI: Proton Pump Inhibitor
🔬 Classification and Pathophysiology
Hypothyroidism classification based on level of hypothalamic-pituitary-thyroid axis dysfunction:
Primary Hypothyroidism (95%)
- Mechanism: Thyroid gland dysfunction, loss of negative feedback
- Lab Pattern: High TSH, low free T4
- Common Causes: Hashimoto's thyroiditis, iodine deficiency, post-RAI, post-surgical
Secondary/Tertiary (5%)
- Mechanism: Pituitary (secondary) or hypothalamic (tertiary) failure
- Lab Pattern: Low or normal TSH, low free T4
- Causes: Pituitary tumors, Sheehan's syndrome, hypothalamic lesions
🎯 Key Concept: Thyroid hormones regulate cellular metabolism by controlling oxygen consumption, heat production, and protein synthesis. Deficiency results in multisystem hypometabolic state affecting cardiovascular, neurologic, and gastrointestinal function.
💊 Thyroid Hormone Replacement
Levothyroxine monotherapy is the standard treatment for most patients:
| Agent | Characteristics | Clinical Use | Key Points |
|---|---|---|---|
| Levothyroxine (T4) | Synthetic T4; converted to active T3 peripherally | First-line for all hypothyroidism | Long half-life (7 days), once-daily dosing, consistent bioavailability |
| Liothyronine (T3) | Synthetic T3; direct active hormone | Myxedema coma, select refractory cases | Short half-life (1 day), higher cardiac risk, requires multiple daily doses |
| Combination T4/T3 | Both prohormone and active hormone | Controversial; not routinely recommended | Limited evidence for superiority over T4 monotherapy |
🎯 Levothyroxine Dosing Strategies
Individualized dosing based on patient characteristics and clinical scenario:
Initial Dosing Guidelines
- Healthy Adults <50 years: 1.6 mcg/kg/day (full replacement dose)
- Elderly or Cardiac Disease: 25 to 50 mcg/day (start low, go slow)
- Severe Hypothyroidism: 12.5 to 25 mcg/day (gradual titration)
- Pregnancy (Known Hypothyroid): Increase pre-pregnancy dose by 25% to 30% immediately
Monitoring and Adjustment
- Initial: Check TSH 6 to 8 weeks after starting or dose change
- Dose Adjustment: 12.5 to 25 mcg increments based on TSH
- Target TSH: 0.5 to 2.5 mU/L for most adults; 1.0 to 5.0 mU/L for elderly
- Stable Patients: Annual TSH monitoring
⚠️ Administration Instructions: Take on empty stomach 30 to 60 minutes before breakfast. Separate from calcium, iron, antacids, and PPIs by at least 4 hours. Maintain consistent timing and brand for stable absorption.
🎯 Special Populations
Critical considerations for specific patient groups:
| Population | Initial Dose | Target TSH | Key Considerations |
|---|---|---|---|
| Pregnancy | Increase by 25-30% | First trimester: 0.1-2.5 mU/L Later: 0.2-3.0 mU/L |
Monitor every 4 weeks; critical for fetal neurodevelopment |
| Elderly (>65 years) | 25-50 mcg/day | 1.0-5.0 mU/L | Higher cardiac risk; slow titration essential |
| Cardiac Disease | 12.5-25 mcg/day | 1.0-5.0 mU/L | Risk of exacerbating angina or arrhythmias |
| Secondary Hypothyroidism | 1.6 mcg/kg/day | Not reliable | Monitor free T4 (target mid-normal range); TSH unreliable |
| Subclinical (TSH 4.5-10) | Consider treatment if symptomatic | 0.5-2.5 mU/L | Treat if TSH >10 mU/L, positive TPO antibodies, or pregnancy |
🆘 Myxedema Coma Management
Life-threatening emergency requiring aggressive multi-modal therapy:
Emergency Protocol
- Levothyroxine IV: Loading dose 200 to 400 mcg, then 50 to 100 mcg daily IV
- Liothyronine IV: 5 to 20 mcg if severe cardiac compromise (optional)
- Hydrocortisone: 100 mg IV every 8 hours (treat potential adrenal insufficiency)
- Supportive Care: Passive rewarming, mechanical ventilation if needed, fluid management
- Treat Precipitants: Infection, medications, cold exposure
🔄 Causes of Treatment Failure
Common reasons for inadequate therapeutic response:
Major Factors Affecting Levothyroxine Efficacy
- Poor Adherence: Most common cause of elevated TSH despite therapy
- Malabsorption: Celiac disease, gastric bypass, inflammatory bowel disease
- Drug Interactions: Calcium, iron, PPIs, bile acid sequestrants (separate by 4 hours)
- Increased Requirements: Pregnancy, weight gain, estrogen therapy, certain medications
- Incorrect Timing: Taking with food or interfering medications
- Wrong Diagnosis: Secondary hypothyroidism treated as primary
📊 Subclinical Hypothyroidism
Management of elevated TSH with normal free T4:
Treatment Indications
- TSH >10 mU/L: Treat all patients
- TSH 4.5 to 10 mU/L: Treat if symptomatic, positive TPO antibodies, goiter, or pregnancy
- Pregnancy: Treat if TSH >2.5 mU/L (first trimester) or >3.0 mU/L (later)
Observation Strategy
- TSH <10 mU/L: Monitor every 6 to 12 months if not treating
- Assess Symptoms: Fatigue, weight gain, cold intolerance
- Check TPO Antibodies: Positive suggests progression risk
🎯 Clinical Pearls
Essential high-yield principles for hypothyroidism management:
- Levothyroxine is treatment of choice; long half-life allows once-daily dosing
- Take on empty stomach 30 to 60 minutes before breakfast for optimal absorption
- Separate from calcium, iron, PPIs, antacids by at least 4 hours
- Start low, go slow in elderly and cardiac patients (12.5 to 25 mcg/day)
- Pregnancy: increase dose by 25% to 30% immediately; monitor TSH every 4 weeks
- Target TSH 0.5 to 2.5 mU/L for most adults; 1.0 to 5.0 mU/L for elderly
- Check TSH 6 to 8 weeks after starting or changing dose
- Secondary hypothyroidism: monitor free T4, not TSH (TSH unreliable)
- Myxedema coma: IV levothyroxine 200 to 400 mcg loading dose plus hydrocortisone
- Subclinical hypothyroidism: treat if TSH >10 mU/L or symptomatic with positive TPO antibodies
🔬 Pharmacology Study Tips:
- Know T4 advantages: Long half-life, predictable conversion to T3, once-daily dosing
- Remember absorption factors: Empty stomach, separate from interfering drugs
- Understand monitoring: TSH for primary, free T4 for secondary hypothyroidism
- Pregnancy critical: Immediate 25% to 30% dose increase; essential for fetal brain development